Without doubt, the discrepant correlation between arteriography and ultrasound will narrow when all institutions performing endarterectomy are employing state-of-the-art color-flow duplex sonographic equip-
The two larger trials12 established without equivocation that stroke-free survival was improved by surgery. The smaller Veterans Administration (VA) Symptomatic Trial was stopped prematurely when the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and the European Carotid Surgery Trial (ECST) established so clearly the benefit of surgery.3 None of these trials based the eligibility for entry into the trials on ultrasound studies; records were kept of the ultrasound observations in the NASCET and VA patients.',3 All trials required that there be demonstrated expertness in the performance of arteriography in the collaborating centers. Intracranial studies were mandated by the NASCET and VA protocols; invasive arteriography was requested in all of them. The trials were not in a position to equip each center with state-of-the-art equipment for noninvasive studies, nor to perform strict quality control measures, including the assurance that expert technologists performed all the studies in all the patients to be randomized. Duplex was in its infancy when the ECST was launched in 1981.
NASCET We are aware that the formulae used by NASCET and ECST give different measures of the degrees of stenosis in the same arteriogram. In their preliminary report of benefit for surgery, the ECST used a larger denominator in the equation (the carotid bulb) than did NASCET (the artery beyond the bulb and the disease). We have reported that 48% of ECST patients previously designated as "severe" (ie, greater than 70% stenosis) became "moderate" (ie, less than 70% stenosis) when remeasured by the NASCET formula.8 The survival curves in both trials when the ECST arteriogram measurements were adjusted to correspond with the NA-SCET measurements and calculations are remarkably similar (Figure) . Both trials have conducted interobserver and intraobserver studies that validate the reproducibility by blinded observers of the respective arteriographic measurements used in NASCET and ECST. Final resolution of the benefit of surgery for the highmoderate patient (50% to 69% stenosis by NASCET measurements and less than 82% stenosis as NASCET measures apply to ECST patients) await the completion of the ongoing phases of NASCET and ECST. When these two trials are completed, it will be simple to resolve the question of whether to use the NASCET method or a modified ECST method as the ideal measure of arteriographic stenosis. It will serve no useful purpose to drop both at this time and adopt an ultrasonographic measurement against which treatment benefit has never been validated.
The confirmation that the NASCET and ECST measurements of stenosis are equally good predictors of ipsilateral stroke is reassuring because the yardstick against which decisions are made about surgery depend for the immediate future upon the degree of stenosis found in an arteriogram. No other group of patients save those with symptoms due to a linear stenosis at and above 70% by arteriography can be claimed to have been shown to benefit from endarterectomy.
Therapeutic decisions and the reproducible index of the degree of narrowing are independent of any discussion of the search for a definition of "true" stenosis. The compelling quest is for a method of measurement that during life predicts ipsilateral ischemic stroke, not what will be seen at surgery or after death. It would be unnecessary, indeed absurd, to recommend that the surgical trials be repeated using noninvasive technology. The search must be for a reproducible method of converting the percentage measurements of NASCET and ECST taken from arteriograms to the newest and best noninvasive method, whatever it proves to be. If this conversion is found to be reliably correlated with the diameter arteriographic measurements, it will be possible then to predict without arteriography which patients will benefit from carotid endarterectomy. That is what we really want. At the present time, this benefit applies to a symptomatic patient with a stenosis of 70% or greater. The accurate identification of a variety of cut-off points may become equally important when the ongoing phase of NASCET and ECST for patients with less than 70% stenosis is completed, and it certainly will be a major requirement if the ongoing asymptomatic studies identify a specific group of patients above a certain level of stenosis who benefit from surgery.
Two vital caveats must be extended to the application of ECST and NASCET results to clinical practice. First and possibly foremost, the surgical procedure must be performed with the skill of the trial surgeons. Otherwise, the benefit of surgery compared to medical care alone will slip away. Second, extreme care will be demanded of those who interpret the images which at this point in time will have to be selective arteriograms.
Finally, skepticism must be accorded to the confidence which Alexandrov and his colleagues have extended to the "eyeballing" method of recording the degree of stenosis. Surely it cannot be claimed to be good science to advocate a method of measurement which cannot be objectively taught? The patients being selected for a surgical procedure which even in the most skilled hands carries a real (albeit small) risk of complicating stroke deserve evaluation that is as free from guesswork as modern radiology departments can provide. Our experience in these trials that have involved thousands of patients has shown us that estimates without careful measurement can be remarkably variable. Overestimation puts patients into the "severe" category when they are not and underestimation denies patients surgery or entry into the "moderate" arm of NASCET and ECST.
